Preliminary injunctions (“PIs”) matter in life sciences patent cases. As often as not, the party which prevails at this stage of the litigation will have the upper hand in settlement negotiations. …
The Russian Intellectual Property Court (IPC) recently revoked an extension (SPC) of Pfizer's Eurasian patent No. 012666 relating to the composition of tofacitinib in relation to the Russian…
In patent law, the concept of “prior art” or “state of the art” describes the universe of information which existed and was made available to the public by means of a written or oral description, by…
In less than 15 days, the Enlarged Board of Appeals (“EBA”) handed down two major decisions in relation to patent validity: (i) one relating to claim construction when assessing the patentability of…
The final week of July usually produces a flurry, and sometimes an avalanche, of decisions from the English Courts as Judges attempt to clear their desks before the holiday period. This year was no…
The use of divisional patent applications in order to ensure flexibility and to keep a patentee’s options open as to the protection it seeks to obtain is established practice in many patent offices…
In the UK, as well as in many other countries, being the first to market with a generic or biosimilar to a leading branded medicine is a critical strategy that can offer a major advantage to a…
G 1/24 addresses the extent to which the description can be used to interpret the claims. As previously discussed, it looks set to be one of the most consequential EPO decisions of the decade. The…
On 9 January 2025 I reported on Parts 1 and 2 of a three-part article in EPI Information by Tamaris Bucher, a Principal Patent Attorney at Novartis Pharma AG, on the current approach to antibody…
